Cited 11 times in
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 심효섭 | - |
dc.contributor.author | 임선민 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 최종락 | - |
dc.date.accessioned | 2017-02-24T07:53:32Z | - |
dc.date.available | 2017-02-24T07:53:32Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146548 | - |
dc.description.abstract | OBJECTIVES: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with advanced NSCLC who have received one or two prior chemotherapy regimens for metastatic disease, ECOG 0-2, and adequate organ function were eligible. Patients received 400mg twice daily sorafenib and 150 mg daily erlotinib in 28-day cycles. Epidermal growth factor receptor mutation and its downstream pathways were analyzed from available tumor samples. Changes in plasma cytokine and angiogenic factors were correlated with clinical outcomes. RESULTS: A total of 46 patients were enrolled. Twenty patients (43%) were never smokers and 35 patients (75%) had adenocarcinoma histology. The overall response rate was 30.4%. Response to sorafenib/erlotinib was observed more commonly in patients with EGFR mutation than in those with EGFR wild type (WT) or EGFR unknown tumors (62.5% vs. 6.7% vs. 34.8%; P=0.013). Likewise, DCR was higher among patients with EGFR mutation than in those with EGFR WT or EGFR unknown tumors (87.5% vs. 46.7% vs. 60.9%; P=0.161). The most frequent adverse events (AEs) of all grades were hand-foot skin reaction (67.4%) followed by acneiform rash (58.7%). CONCLUSION: Sorafenib combined with erlotinib is well-tolerated with manageable toxicity and appears to be effective against advanced NSCLC with one or two prior line of systemic treatment (NCT00801385). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.format.extent | 1~8 | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/mortality | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology* | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Erlotinib Hydrochloride/administration & dosage | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/genetics | - |
dc.subject.MESH | Lung Neoplasms/mortality | - |
dc.subject.MESH | Lung Neoplasms/pathology* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Niacinamide/administration & dosage | - |
dc.subject.MESH | Niacinamide/analogs & derivatives | - |
dc.subject.MESH | Phenylurea Compounds/administration & dosage | - |
dc.subject.MESH | Proto-Oncogene Proteins p21(ras)/genetics | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/antagonists & inhibitors | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/genetics | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806) | - |
dc.type | Article | - |
dc.publisher.location | Ireland | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pathology | - |
dc.contributor.googleauthor | Sun Min Lim | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Sang-We Kim | - |
dc.contributor.googleauthor | Seok Yun Kang | - |
dc.contributor.googleauthor | Dae Seog Heo | - |
dc.contributor.googleauthor | Heung Tae Kim | - |
dc.contributor.googleauthor | Dae Ho Lee | - |
dc.contributor.googleauthor | Dong-Wan Kim | - |
dc.contributor.googleauthor | Minkyu Jung | - |
dc.contributor.googleauthor | Jin-Hyuk Choi | - |
dc.contributor.googleauthor | Hyo Sup Shim | - |
dc.contributor.googleauthor | Jong Rak Choi | - |
dc.contributor.googleauthor | Joo-Hang Kim | - |
dc.identifier.doi | 10.1016/j.lungcan.2015.12.005 | - |
dc.contributor.localId | A02219 | - |
dc.contributor.localId | A03369 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04182 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 26898607 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169500215301240 | - |
dc.subject.keyword | Erlotinib | - |
dc.subject.keyword | Non-small-cell lung cancer | - |
dc.subject.keyword | Sorafenib | - |
dc.contributor.alternativeName | Shim, Hyo Sup | - |
dc.contributor.alternativeName | Lim, Sun Min | - |
dc.contributor.alternativeName | Jung, Min Kyu | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Choi, Jong Rak | - |
dc.contributor.affiliatedAuthor | Shim, Hyo Sup | - |
dc.contributor.affiliatedAuthor | Lim, Sun Min | - |
dc.contributor.affiliatedAuthor | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Jong Rak | - |
dc.citation.volume | 93 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 8 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.93 : 1-8, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 45179 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.